High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes

L. J. M. Boonman-de Winter · F. H. Rutten · M. J. M. Cramer · M. J. Landman · A. H. Liem · G. E. H. M. Rutten · A. W. Hoes

Received: 24 January 2012 / Accepted: 11 April 2012 / Published online: 18 May 2012
© The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract

Aims/hypothesis The aim of this study was to assess the prevalence of (unknown) heart failure and left ventricular dysfunction in older patients with type 2 diabetes.

Methods In total, 605 patients aged 60 years or over with type 2 diabetes in the south west of the Netherlands participated in this cross-sectional study (response rate 48.7%), including 24 with a cardiologist-confirmed diagnosis of heart failure. Between February 2009 and March 2010, the patients without known heart failure underwent a standardised diagnostic work-up, including medical history, physical examination, ECG and echocardiography. An expert panel used the criteria of the European Society of Cardiology to diagnose heart failure.

Results Of the 581 patients studied, 161 (27.7%; 95% CI 24.1%, 31.4%) were found to have previously unknown heart failure: 28 (4.8%; 95% CI 3.1%, 6.6%) with reduced ejection fraction, and 133 (22.9%; 95% CI 19.5%, 26.3%) with preserved ejection fraction. The prevalence of heart failure increased steeply with age. Heart failure with preserved ejection fraction was more common in women. Left ventricular dysfunction was diagnosed in 150 patients (25.8%; 95% CI 22.3%, 29.4%); 146 (25.1%; 95% CI 21.6%, 28.7%) had diastolic dysfunction.

Conclusions/interpretation This is the first epidemiological study that provides exact prevalence estimates of (previously unknown) heart failure and left ventricular dysfunction in a representative sample of patients with type 2 diabetes. Previously unknown heart failure and left ventricular dysfunction are highly prevalent. Physicians should pay special attention to ‘unmasking’ these patients.

Keywords Diagnosis · Echocardiography · Epidemiology · Heart failure · Left ventricular dysfunction · Prevalence · Type 2 diabetes

Abbreviations

A Atrial contraction
E Early diastolic mitral flow velocity
E’ Early diastolic mitral annular velocity

M. J. Landman
Meander Hospital,
Amersfoort, the Netherlands

A. H. Liem
Department of Cardiology, Admiraal de Ruyter Hospital,
Goes, the Netherlands

Present address:
M. J. Landman
Van Hardenbroeklaan 21,
3832CK Leusden, the Netherlands

Present address:
A. H. Liem
Department of Cardiology, Sint Franciscus Hospital,
Rotterdam, the Netherlands
Early filling to early diastolic mitral annular velocity ratio
Early-to-atrial left ventricular filling ratio
European Society of Cardiology
Heart failure with preserved ejection fraction
Heart failure with reduced ejection fraction
Left atrial
Left ventricular ejection fraction
Modification of diet in renal disease
N-terminal pro B-type natriuretic peptide
New York Heart Association
Systolic-to-diastolic pulmonary venous flow ratio

Introduction

Cardiovascular diseases are of major importance in patients with type 2 diabetes, accounting for up to 80% of the excess mortality in these patients [1]. Processes underlying the excess cardiovascular mortality risk include coronary atherosclerosis, generalised microvascular disease and autonomic neuropathy [1]. In addition, myocardial abnormalities (‘diabetic cardiomyopathy’) and heart failure seem to play a role [2, 3]. In general, underdiagnosis of heart failure is common [4]; a prevalence of unrecognised heart failure of up to 20.5% has been reported in specific patient groups, such as patients with chronic obstructive pulmonary disease [4, 5]. Previously reported heart failure prevalence estimates in patients with type 2 diabetes were based on medical records or heart failure scores, lacking echocardiography in all patients. Reported prevalence ranged from 9.5% to 22.3% [6–9], and the incidence of heart failure in patients with type 2 diabetes was about 2.5 times that in people without diabetes [10]. In one study, echocardiography was used to diagnose heart failure with reduced ejection fraction (HFREF), resulting in a prevalence of 7.7%, but diastolic dysfunction and heart failure with preserved ejection fraction (HFPEF) was not assessed [11].

To our knowledge, exact prevalence estimates of (unrecognised) heart failure, with and without reduced ejection fraction, and systolic and diastolic dysfunction in a representative sample of all older patients with type 2 diabetes are lacking. We therefore assessed this prevalence in patients aged 60 years and older with type 2 diabetes, all undergoing echocardiography.

Methods

Participants The study was conducted between February 2009 and March 2010, in the province of Zeeland, in the south west of the Netherlands. We were able to invite a representative group of patients with type 2 diabetes, at least for Western Europe, because all patients with type 2 diabetes in this region are enrolled in the Diabetes Care programme of the Center for Diagnostic Support in Primary Care (SHL), including those (co-)treated by hospital specialists (~50,000 patients during the period of this study). Of all the patients with type 2 diabetes from the participating physicians in this study, 1,243 were 60 years or older, and were invited.

All participants gave written informed consent, and the institutional review board of the University Medical Center Utrecht and the Admiraal de Ruyter Hospital in Goes, the Netherlands approved the study protocol. The protocol of the study has been published previously [12] and the study is registered at www.cemo.nl, NL2271704108.

Measurements The patients without a cardiologist-confirmed diagnosis of heart failure (i.e. including echocardiographic evidence of left ventricular dysfunction) underwent a standardised diagnostic assessment, which was executed in the cardiology outpatient department of the Admiraal de Ruyter Hospital in Goes. Information on duration of diabetes, smoking habits and comorbidities was obtained from the patients and the registry. Patients were asked to bring their medication packages so that current drug treatment could be checked. The presence of angina pectoris and shortness of breath was assessed with the WHO questionnaires [13]. Symptoms and signs were assessed by a trained physician in a standardised manner. A standard 12-lead ECG was recorded and classified according to the Minnesota coding criteria by a single experienced cardiologist, blinded to all other test results. Systolic and diastolic blood pressure was measured once electronically, after 5 min of rest in a supine position. Blood was taken within 2 weeks of the diagnostic assessment, with measurement of serum B-type natriuretic peptide (NT-proBNP), blood glucose, creatinine and HbA1c. NT-proBNP was measured with a non-competitive immunoradiometric assay (Roche Diagnostics, Mannheim, Germany).

Echocardiography was performed with a General Electric, Vivid 7 imaging system device (GE Vingmed Ultrasound AS, Horten, Norway) by well-trained and experienced cardiac sonographers. Variables from Doppler analysis, M-mode echocardiography and two-dimensional transthoracic echocardiography were used. Where image quality was adequate, left-ventricular ejection fraction (LVEF) was calculated from the endocardial surface tracings in the apical four-chamber view and two-chamber view, using Simpson’s rule (disc summation method) [14, 15].

LVEF could be assessed in 97.5% of the patients by a quantitative method or the two-dimensional visual estimate method (‘eyeballing’) [16]. The accuracy of eyeballing has been validated previously [17]. Wall motion abnormalities were visually analysed and summarised in a wall motion...
score [18]. Left ventricular mass was calculated using M-mode measurements and the formula of Devereux and Reichek [19]. Valve regurgitation was graded semi-quantitatively, and, in the case of aortic stenosis, the pressure gradient was measured. Left atrial (LA) volume was assessed by the biplane area-length method from apical four- and two-chamber views [20]. Indexed values were corrected for body surface area. The cut-off values 28 and 34 ml/m² were used for normal and definitely increased LA volume index, respectively [21].

Mitral inflow and pulmonary venous inflow were assessed by means of pulsed-wave Doppler echocardiography. From the mitral inflow profile, the early diastolic mitral flow velocity (E) and atrial contraction (A)-wave velocity and the E-deceleration time were measured, and the early-to-atrial left ventricular filling ratio (E/A) was calculated. The flow velocities of the left or right upper pulmonary vein were recorded, and the ratio of systolic to diastolic forward flow (S/D) was calculated. We measured the peak velocity of the tricuspid regurgitated signal with continuous-wave Doppler and calculated the systolic pulmonary artery pressure with the modified Bernoulli’s equation [22].

Diastolic function was assessed by an approach that integrates Doppler measurements of the mitral inflow and Doppler tissue imaging of the mitral annulus using the early diastolic septal annular velocity (e’) [23]. E’(early diastolic mitral annular velocity) is a measure of the relaxation of the ventricle. We calculated the early filling to early diastolic mitral annular velocity ratio (E/e’) as a measure of filling pressures [24].

Criteria to establish diastolic and systolic dysfunction and heart failure An E/e’ value below 8 was considered normal, and 8–15 indeterminate. An E/e’≥15 was considered abnormal [25], and these patients were classified as having diastolic dysfunction. When E/e’ was between 8 and 15 and a septal e’ <8 cm/s, a combination of elevated indexed LA volume or S/D<1 were also classified as having diastolic dysfunction. When patients with atrial fibrillation, we considered an elevated indexed LA volume sufficient to classify as diastolic dysfunction.

Systolic dysfunction was defined as an LVEF≤45% by echocardiography, and diastolic dysfunction graded as I, II or III in combination with an LVEF>45%.

To be classified as heart failure, systolic or diastolic dysfunction had to be present in combination with one or more suggestive symptoms (e.g. orthopnoea, paroxysmal nocturnal dyspnœa, fatigue, peripheral oedema, nocturia more than twice a night) and one or more signs indicative of heart failure (e.g. peripheral or pulmonary fluid retention or raised jugular venous pressure). In patients who used diuretics, signs of volume overload were not obligatory to classify the presence of heart failure.

Presence or absence of dysfunction and heart failure was determined by an expert panel consisting of two cardiologists (MJC and MJL) and one general practitioner with special interest in heart failure (FHR). The panel was guided by the diagnostic principles of the most recent guidelines for heart failure of the European Society of Cardiology (ESC) [27]. All available results from the diagnostic assessment except for the NT-proBNP results were used. This was done because we wanted to assess the diagnostic value of NT-proBNP separately. The expert panel also established the most likely cause of heart failure based on the diagnostic assessment, including ECG and echocardiography. In the case of no consensus, the majority decision was used.

A random sample of 63 (10.7%) patients was reclassified by the expert panel blinded to the original classification. In five cases, the diagnosis ‘presence or absence of heart failure’ did not correspond to the original diagnosis (κ 0.82, SD 0.08). Incongruent cases most often occurred between diastolic dysfunction and diastolic heart failure.

Data analyses We calculated age- and sex-specific prevalence rates of unrecognised HFREF and HFPEF and systolic and diastolic dysfunction. Overall heart failure prevalence estimates were calculated by including patients who already had a cardiologist-confirmed diagnosis of heart failure at baseline in both the numerator and denominator. Prevalence estimates are given for 5-year age groups and for men and women separately. Binomial confidence intervals (95%)

| Variable       | Normal                                      | Impaired relaxation (grade I) | Pseudo normal filling (grade II) | Restrictive filling (grade III) |
|----------------|---------------------------------------------|------------------------------|---------------------------------|---------------------------------|
| E/A (cm/s)     | 0.75≤E/A<1.5                                | E/A≥0.75                     | 0.75≤E/A<1.5                   | E/A>1.5                        |
| DT (ms)        | 140≤DT<320                                  | ≥180                         | 140≤DT<320                     | DT>320                         |
| S/D            | ≥1                                          | ≥1                           | <1                             | <1                             |

DT, deceleration time
were calculated for overall prevalence rates. Data with a skewed distribution were summarised as medians with IQRs. Data were analysed using SPSS Windows version 16.0 for Windows (SPSS, Chicago, IL, USA).

Results

Participants In total, 605 patients agreed to participate (response rate 48.7%), 581 of them without a cardiologist-confirmed diagnosis of heart failure. The mean age of the 605 responders was 71.5 (SD 7.5) years, and 54.0% (95% CI 50.1%, 58.0%) were male. The mean HbA1c was 6.7% (SD 0.6%) (49.0 [SD 6.1] mmol/mol), creatinine 81.7 (SD 15.9) μmol/l, and modification of diet in renal disease (MDRD) 82.8 (SD 15.4) ml min⁻¹ 1.73 m⁻². The mean age of non-responders was 77.0 (SD 9.1) years, the percentage of men 43.4 (95% CI 39.6, 47.3), HbA1c 6.7% (SD 0.6%) (49.4 [SD 6.8] mmol/mol), creatinine 84.5 (SD 19.7) μmol/l and MDRD 79.0 (SD 17.9) ml min⁻¹ 1.73 m⁻². Table 2 shows the characteristics of the participants previously not known to have heart failure.

Prevalence of heart failure Of the 581 patients previously not known to have heart failure, 161 were diagnosed with heart failure (prevalence 27.7%; 95% CI 24.1%, 31.4%); 28 (4.8%; 95% CI 3.1%, 6.6%) with HFREF, 150 (24.8%; 95% CI 19.5%, 26.3%) with HFPEF, and none with right-sided heart failure. Of those with HFREF, nine had an LVEF ≤ 40%, and 19 an LVEF between 40% and 45%. The overall prevalence of heart failure among the 605 patients was 185 (30.6%; 95% CI 26.9%, 34.2%): 35 (5.8%; 95% CI 3.9%, 7.6%) with HFREF, and 150 (24.8%; 95% CI 21.4%, 28.2%) with HFPEF. In addition, five patients were classified as having possible heart failure by the expert panel: one with HFREF, three with HFPEF, and one with right-sided heart failure. Sex-specific prevalence rates for 5-year age groups of previously unknown HFREF and HFPEF are shown in Table 3. The prevalence of heart failure increased with age, and was overall higher in female than male patients (31.0% vs 24.8%). The prevalence of HFREF was higher in men (6.8%) than women (3.0%).

Prevalence of left ventricular dysfunction In addition, left ventricular dysfunction was diagnosed in 150 patients (25.8%; 95% CI 22.3%, 29.4%); nearly all (97.3%) had diastolic dysfunction. Of the 581 patients, 264 (45.4%) had ‘normal’ left ventricular function, although 65 (11.2%) had an LVEF 45–55% (without diastolic dysfunction) and could be considered to have suboptimal systolic left ventricular function. Prevalence rates for diastolic and systolic dysfunction are shown in Table 4. The systolic dysfunction was higher in men (1.3%) than in women (0%).

Discussion

Our study in a large representative group of older patients with type 2 diabetes showed that the prevalence of previously unknown heart failure is very high (27.7%), steeply increases with age, and is overall higher in women (31.0%) than men (24.8%). The prevalence is significantly higher in patients with a BMI ≥ 30 kg/m² (38.7% vs 23.4%), in patients with dyspnoea (46.6% vs 13.3%), in patients complaining of fatigue (45.6% vs 16.1%) and treated for hypertension (31.2% vs 21%). The majority (82.6%) of the patients with newly detected heart failure had HFPEF (prevalence 22.9%). Moreover, the prevalence of left ventricular dysfunction (25.8%), mainly diastolic dysfunction (25.1%), was high. Only 264 (45.4%) of all investigated patients had ‘normal’ left ventricular function, including 65 (11.2%) with a suboptimal LVEF of 45–55%.

The high prevalence of previously unknown heart failure could be due to patients with symptoms of heart failure not going to a physician or physicians not asking the patient about these symptoms. A further possibility is that when patients do present with these symptoms, physicians do not recognise heart failure.

Hypertension was presumed to be the most important possible cause of heart failure in our study population,
Table 2 Characteristics of patients with type 2 diabetes aged ≥60 years, previously not known to have heart failure, categorised as newly detected heart failure or no heart failure after the diagnostic assessment

| Characteristic                                      | All patients (n=581) | Newly detected heart failure (n=161) | No heart failure (n=420) | p value |
|-----------------------------------------------------|----------------------|-------------------------------------|--------------------------|---------|
| Mean (SD) age (years)a                              | 71.6 (7.4)           | 74.5 (7.7)                          | 70.5 (6.9)               | <0.001  |
| Male                                                | 310 (53.4)           | 77 (47.8)                           | 233 (55.5)               | 0.098   |
| Median (IQR) duration of diabetesa                  | 5.5 (3.0, 15.2)      | 6.3 (3.3, 10.2)                     | 5.1 (3.0, 10.1)          | 0.292   |
| Mean (SD) HbA1c (%)                                 | 6.7 (0.7)            | 6.7 (0.7)                           | 6.7 (0.7)                | 0.519   |
| Mean (SD) HbA1c (mmol/mol)                          | 49.5 (8.0)           | 49.9 (8.2)                          | 49.4 (7.4)               | 0.519   |
| Current smoker                                      | 80 (13.8)            | 24 (14.9)                           | 56 (13.3)                | 0.622   |
| BMI >30 kg/m²                                       | 163 (28.1)           | 63 (39.1)                           | 100 (23.8)               | <0.001  |
| Comorbiditiesb                                      |                      |                                     |                          |         |
| Ischaemic heart diseasec                            | 108 (18.6)           | 50 (31.1)                           | 58 (13.8)                | <0.001  |
| Atrial fibrillation                                 | 42 (7.2)             | 20 (12.4)                           | 22 (5.2)                 | 0.003   |
| Stroke/TIA                                          | 55 (9.5)             | 23 (14.3)                           | 32 (7.6)                 | 0.014   |
| Peripheral arterial disease                         | 39 (6.7)             | 21 (13.0)                           | 18 (4.3)                 | <0.001  |
| Hypertension                                        | 381 (65.6)           | 119 (73.9)                          | 262 (62.4)               | 0.009   |
| Asthma/COPD                                         | 71 (12.2)            | 28 (17.4)                           | 43 (10.2)                | 0.018   |
| Renal dysfunction                                   | 26 (4.5)             | 11 (6.8)                            | 15 (3.6)                 | 0.089   |
| Thyroid disease                                     | 43 (7.4)             | 15 (9.3)                            | 28 (6.7)                 | 0.275   |
| Medication                                          |                      |                                     |                          |         |
| Loop diuretics                                      | 36 (6.2)             | 22 (13.7)                           | 14 (3.3)                 | <0.001  |
| Thiazide diuretics                                  | 167 (28.7)           | 51 (31.7)                           | 116 (27.6)               | 0.333   |
| ACE-inhibitors/angiotensin receptor blockers        | 306 (52.7)           | 102 (63.4)                          | 204 (48.6)               | <0.001  |
| Aldosterone antagonist                              | 4 (0.7)              | 1 (0.6)                             | 3 (0.7)                  | 0.903   |
| β-Blockers                                          | 209 (36.0)           | 84 (52.2)                           | 125 (29.8)               | <0.001  |
| Dihydropyridines                                    | 30 (5.2)             | 14 (8.7)                            | 16 (3.8)                 | 0.017   |
| Non-dihydropyridines                                | 65 (11.2)            | 26 (16.1)                           | 39 (9.3)                 | 0.019   |
| Metformin                                           | 302 (52.0)           | 91 (56.5)                           | 211 (50.2)               | 0.175   |
| Sulfonilurea derivatives                            | 213 (36.7)           | 59 (36.6)                           | 154 (36.7)               | 0.996   |
| Thiazolidinediones                                  | 17 (2.9)             | 4 (2.5)                             | 14 (3.1)                 | 0.696   |
| Insulin                                             | 73 (12.6)            | 23 (14.3)                           | 50 (11.9)                | 0.438   |
| Symptoms                                            |                      |                                     |                          |         |
| Dyspnoea                                            | 251 (43.2)           | 117 (72.7)                          | 134 (31.9)               | <0.001  |
| Fatigue                                             | 228 (39.2)           | 104 (64.6)                          | 124 (29.5)               | <0.001  |
| Paroxysmal nocturnal dyspnoea or orthopnoea         | 61 (10.5)            | 31 (19.3)                           | 30 (7.1)                 | <0.001  |
| Swollen ankles                                      | 161 (27.7)           | 75 (46.6)                           | 86 (20.5)                | <0.001  |
| Nocturia                                            | 260 (44.8)           | 94 (58.4)                           | 166 (39.5)               | <0.001  |
| Angina pectoris                                     | 48 (8.3)             | 24 (14.9)                           | 24 (5.7)                 | <0.001  |
| Palpitations                                        | 113 (19.4)           | 43 (26.7)                           | 70 (16.7)                | 0.006   |
| Additional tests                                    |                      |                                     |                          |         |
| Abnormal ECGd                                       | 342 (58.9)           | 128 (79.5)                          | 214 (51.0)               | <0.001  |
| NT-proBNP ≥15 pmol/l (125 pg/ml)                     | 183 (31.5)           | 87 (54.0)                           | 96 (22.9)                | <0.001  |
| Median (IQR) NT-proBNP                              | 9.0 (5.18)           | 16.0 (9, 41)                        | 8 (5, 14)                | <0.001  |
| Echocardiographic variables                         |                      |                                     |                          |         |
| Mean (SD) LVEF                                      | 60.2 (8.2)           | 56.9 (9.4)                          | 61.4 (7.4)               | <0.001  |
| LVEF >55%                                           | 438 (75.4)           | 107 (66.5)                          | 331 (78.8)               | 0.002   |
| LVEF 45–55%                                         | 117 (20.1)           | 34 (21.1)                           | 83 (19.8)                | 0.430   |
| LVEF ≤45%                                           | 26 (4.5)             | 20 (12.4)                           | 6 (1.4)                  | <0.001  |
| Mean (SD) c'                                       | 0.06 (0.02)          | 0.06 (0.2)                          | 0.07 (0.2)               | <0.001  |
according to the panel. Previous studies have shown that hypertension generates a high population attributable risk of heart failure [28] and diastolic left ventricular dysfunction [29]. The exact reason for the high prevalence of diastolic dysfunction is not known, although it may be related to early stages of so-called ‘diabetic cardiomyopathy’ [30]. Our finding that the majority of the patients had an E/A ratio <1, and 52.3% had an E/A ratio <0.75, supports this idea. A low E/A ratio has been linked to early stages of diabetic cardiomyopathy [29, 31].

Several limitations of our study should be discussed. The relatively high blood pressure values could be the result of the single measurement used in our study. Importantly, this had no influence on the prevalence estimates of the cause of heart failure adjudged by the panel, since the panel used a history of high blood pressure rather than current blood pressure levels. NT-proBNP levels were not available to the panel, to prevent incorporating bias for the diagnostic part of the study that will be performed. This may have had some influence on the panel’s diagnosis, although the effect is likely to be small because, in all participants, a complete echocardiographic assessment, including tissue Doppler imaging measurements, was available. When evaluating the possible causes of heart failure, it is important to consider that the panel judged ‘likely’ causes on the basis of the diagnostic assessment, but without specific and detailed further investigations. Under-rating the importance of ischaemia as the possible cause of heart failure is therefore likely.

One of the strengths of the study is a relatively high response rate (48.7%) compared with other population-based studies involving extensive diagnostic testing [5]. As can be expected, the non-responders were older and probably more fragile than the participants. This may have led to a limited underestimation of the prevalence. Importantly, the clinical applicability of our results is high, because we studied patients who were able and willing to undergo the relevant diagnostic investigations, as in every day clinical practice. Another strength of our study is that

### Table 2

| Characteristic                           | All patients (n=581) | Newly detected heart failure (n=161) | No heart failure (n=420) | p value |
|-----------------------------------------|---------------------|-------------------------------------|-------------------------|---------|
| Mean (SD) E/e'                          | 9.5 (3.4)           | 11.4 (5.0)                          | 8.8 (2.3)               | <0.001  |
| Mean (SD) LA volume index (ml/m²)       | 27.7 (9.0)          | 32.6 (10.3)                         | 25.9 (7.8)              | <0.001  |
| Mean (SD) LVED volume index (ml/m²)     | 43.8 (14.9)         | 47.7 (18.1)                         | 42.4 (13.4)             | 0.002   |
| Diastolic dysfunction grade I           | 290 (50.5)          | 141 (89.8)                          | 149 (35.7)              | <0.001  |
| Diastolic dysfunction grade II          | 13 (2.3)            | 11 (7.0)                            | 2 (0.5)                 | <0.001  |
| Diastolic dysfunction grade III         | 3 (0.5)             | 3 (1.9)                             | 0 (0.0)                 | 0.005   |

Values are number (%) unless stated otherwise

- a At time of investigation
- b Comorbidities mentioned by the patient during history taking
- c Prior myocardial infarction, angina pectoris, coronary bypass grafting or percutaneous intervention
- d Any abnormality

COPD, chronic obstructive pulmonary disease; LVED, left ventricular end diastolic; TIA, transient ischaemic attack

### Table 3

Prevalence of previously unknown HFREF and HFPEF stratified by age and sex in patients with type 2 diabetes aged ≥60 years

| Age (years) | Male | Female | Total |
|-------------|------|--------|-------|
|             | n    | HFREF  | HFPEF | All HF | n    | HFREF  | HFPEF | All HF | n    | HFREF  | HFPEF | All HF |
| 60–64       | 85   | 3 (3.5)| 14 (16.5)| 17 (20.0)| 60   | 1 (1.7)| 6 (10.0)| 7 (11.7)| 145  | 4 (2.8)| 20 (13.8)| 24 (16.6)|
| 65–69       | 64   | 3 (4.7)| 10 (15.6)| 13 (20.3)| 67   | 2 (3.0)| 13 (19.4)| 15 (22.4)| 131  | 5 (3.8)| 23 (17.6)| 28 (21.4)|
| 70–74       | 65   | 4 (6.2)| 6 (9.2) | 10 (15.4)| 51   | 0 (0.0)| 19 (37.3)| 19 (37.3)| 116  | 4 (3.4)| 25 (21.6)| 29 (25)  |
| 75–80       | 49   | 3 (6.1)| 9 (18.4)| 12 (24.5)| 44   | 2 (4.5)| 20 (45.5)| 22 (50.0)| 93   | 5 (5.3)| 29 (31.2)| 34 (36.6)|
| ≥80         | 47   | 7 (14.9)| 18 (38.3)| 25 (53.2)| 49   | 3 (6.1)| 18 (36.7)| 21 (42.9)| 96   | 10 (10.4)| 36 (37.5)| 46 (47.9)|
| All ages    | 310  | 20 (6.8)| 57 (18.4)| 77 (24.8)| 271  | 8 (3.0)| 76 (28.0)| 84 (31.0)| 581  | 28 (4.8)| 133 (22.9)| 161 (27.7)|

Values are number (%)
participants underwent all the diagnostic tests required to classify heart failure. The use of Doppler tissue imaging allowed us to measure left ventricular relaxation and filling pressures, largely independently of load, in a reproducible and feasible way \[24, 25, 27, 32\]. Illustrating the good image quality was the availability of LVEF estimations in almost all patients (97.5%). Moreover, we aimed to prevent overdiagnosis of diastolic dysfunction and HFPEF by applying age-adjusted cut-off values and using strict criteria for diastolic dysfunction \[24, 25\]. The use of consensus diagnosis by an outcome panel is an established method in case an irreproachable reference standard is lacking, as is the case for heart failure \[33, 34\]. Outcome panels have been successfully used in previous studies on heart failure by our group \[35\]. In our study, the reproducibility was high (κ 0.82, SD 0.08), and comparable to previous studies \[5\]. The prevalence of previously unknown heart failure in our study (27.7%) is even higher than reported in patients aged 65 years and older with chronic obstructive pulmonary disease \[5\]. The overall prevalence of heart failure (30.6%) in our study is about four times higher than expected in people aged 60 years and older in the general population \[36\]. Several previous studies reported a lower prevalence of heart failure in patients with type 2 diabetes. Bertoni et al \[6\] reported 22.3% in patients with an average age of 74 years, with the diagnosis of heart failure based on insurance claims data. Two other studies reported a prevalence of 11.8%, with the diagnosis of heart failure based on heart failure scores, without the use of echocardiography \[7, 9\]. Only Davis et al \[11\] used echocardiography to diagnose heart failure; however, only the prevalence of HFREF (7.7%) was assessed, and not HFPEF.

The prevalence of left ventricular dysfunction in our study, when we include those diagnosed with heart failure, would be 53.5%: 48.0% diastolic dysfunction and 5.5% systolic dysfunction. In addition, 11.2% had suboptimal

### Table 4

| Age (years) | Male | Female | Total |
|------------|------|--------|-------|
|            | n    | S-Dys  | D-Dys | A-Dys | n    | S-Dys  | D-Dys | A-Dys | n    | S-Dys  | D-Dys | A-Dys |
| 60–64      | 85   | 0      | 28 (32.9) | 28 (32.9) | 60   | 0      | 13 (21.7) | 13 (21.7) | 145  | 0      | 41 (28.3) | 41 (28.3) |
| 65–69      | 64   | 1 (1.6) | 10 (15.6) | 11 (17.2) | 67   | 0      | 20 (29.9) | 20 (29.9) | 131  | 1 (0.8) | 30 (22.9) | 31 (23.6) |
| 70–74      | 65   | 2 (3.1) | 22 (33.8) | 24 (36.9) | 51   | 0      | 14 (27.5) | 14 (27.5) | 116  | 2 (1.7) | 36 (31.0) | 38 (32.8) |
| 75–80      | 49   | 1 (2.0) | 15 (30.6) | 16 (32.7) | 44   | 0      | 10 (22.7) | 10 (22.7) | 93   | 1 (1.1) | 25 (26.9) | 21 (28.0) |
| ≥80        | 47   | 0      | 7 (14.9)  | 7 (14.9)  | 49   | 0      | 7 (14.3)  | 7 (14.3)  | 96   | 0      | 14 (14.6) | 14 (14.6) |
| All ages   | 310  | 4 (1.3) | 82 (26.5) | 86 (29.0) | 271  | 0      | 64 (23.6) | 64 (23.6) | 581  | 4 (0.7) | 146 (25.1) | 150 (25.8) |

Values are number (%)

A-Dys, all dysfunction; D-Dys, diastolic dysfunction; S-Dys, systolic dysfunction

### Table 5

| Possible cause/NYHA class | HFREF (n=28) | HFPEF (n=133) | All HF (n=161) |
|---------------------------|--------------|---------------|---------------|
| Prior myocardial infarction | 13 (46.4) | 24 (18.0) | 37 (23.0) |
| Other ischaemic heart diseasea | 14 (50) | 50 (37.6) | 64 (39.8) |
| Hypertension               | 18 (64.3) | 114 (85.7) | 132 (82.0) |
| Hypertension with left ventricular hypertrophy | 13 (46.4) | 82 (61.7) | 95 (59.0) |
| Atrial fibrillation        | 2 (7.1) | 15 (11.3) | 17 (10.6) |
| Other rhythm and/or conduction disturbances | 3 (10.7) | 5 (3.8) | 8 (5.0) |
| Valvular disease           | 8 (28.6) | 30 (22.6) | 38 (23.6) |
| Diabetic cardiomyopathy    | 12 (42.9) | 36 (27.1) | 48 (29.8) |
| Chronic obstructive pulmonary disease | 5 (17.9) | 9 (6.8) | 14 (8.7) |
| Other                      | 3 (10.7) | 9 (6.8) | 12 (7.5) |
| NYHA class                 |              |              |               |
| II                        | 22 (78.6) | 98 (73.7) | 120 (74.5) |
| III                       | 4 (14.3)  | 35 (26.3) | 39 (24.2) |
| IV                        | 2 (7.1)   | 0   | 2 (1.2) |

Values are number (%) unless stated otherwise. The panel could adjudicate more than one possible cause. aAngina pectoris, coronary artery bypass grafting or percutaneous coronary intervention

HF, heart failure
systolic ventricular dysfunction (LVEF 45–55%). Henry et al [37] reported high prevalence rates of ventricular dysfunction among older patients with type 2 diabetes, with similar values for diastolic dysfunction (47%) and a higher prevalence of systolic dysfunction (30%). Their definition of systolic dysfunction, namely LVEF ≤55% instead of our definition of LVEF ≤45%, is the probable cause of this higher prevalence.

Screening of patients with type 2 diabetes should be considered in the light of the high rates of prevalence (27.7%) of previously unknown heart failure in older patients with type 2 diabetes observed in our study. Physicians should be constantly alert for signs and symptoms indicative of heart failure in these patients. In addition, echocardiography and/or ECG or B-type natriuretic peptide measurements could be part of the yearly monitoring. We need to determine which screening strategy is the most efficient. Although evidence on how to optimally treat patients with HFPEF is scarce, there is consensus that at least optimising blood pressure and reducing heart rate in patients with tachycardia is needed, combined with optimal treatment of (cardiac) comorbidities [38, 39]. An annual check for the presence of heart failure in patients with type 2 diabetes is not yet advised in the diabetes guidelines [40]. Our results could form the evidence base for such a recommendation.

Acknowledgements We thank the participating patients, general practitioners and their assistants in Zeeland, the Netherlands. We thank the sonographers, research nurses and medical doctors of the Admiral de Ruyter Hospital (S. Bolijn-Ahrens, L. Valentijn-Kodde, I. van Maris, L. den Engelsman-Ippel and A. Polderman, M. Godrie, G. Reiijnierse-Buitenwerf, C. Kievit, J. de Vogel and D. de Witte) for their help with data acquisition. We thank the research coordinators (A. van der Smissen-van Meel, J. Bossers-van Rijkevorsel, C. Bakx-van Baal, and L. van Gool-Messelinck) of WECOR/SHL-Groep for their help with data acquisition and data management and board member of WECOR/SHL-Groep P. van Hessen for her initiation and support. We thank P. Zuthoff, UMC-Utrecht Julius Center, for statistical support, and S. Carvalho, UMC-Utrecht Julius Center, for supporting the panel.

Funding An unrestricted research grant was obtained from Fonds Nuts Ohra (grant number 0702086).

Duality of interest The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement LJB was responsible for the conception, design, data acquisition, analysis and interpretation, drafted the article and had full access to all the data in the study and takes responsibility for the integrity of the data, the accuracy of the data analysis and contents of the article. FHR participated in the conception, design, data acquisition and interpretation, and revision of the article. MJL participated in the design, data interpretation and revision of the article. MJC and MJC participated in the data interpretation and revision of the article. FHR, MJC and MJL were panel members. AHL participated in the data acquisition and revision of the article. GER participated in the design of the study and revision of the article. AWH is responsible for conception and design of the study and revision of the article. All authors read and approved the final manuscript.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Blendea MC, McFarlane SI, Isenovic ER, Gick G, Sowers JR (2003) Heart disease in diabetic patients. Curr Diab Rep 3:223–229
2. Giles TD (2003) The patient with diabetes mellitus and heart failure: at-risk issues. Am J Med 115(Suppl 8A):107S–110S
3. Giles TD, Sander GE (2004) Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations. Cardiol Clin 22:553–568
4. Wheeldon NM, MacDonald TM, Flucker CJ, McKendrick AD, McDevitt DG, Struthers AD (1993) Echocardiography in chronic heart failure in the community. Q J Med 86:17–23
5. Rutenberg FH, Cramer MJ, Grobbée DE et al (2005) Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 26:1887–1894
6. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr (2004) Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27:699–703
7. Nichols GA, Hillier TA, Erbey JR, Brown JB (2001) Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24:1614–1619
8. Amato L, Paolisso G, Cacciatori F et al (1997) Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 23:213–218
9. Thrainsdottir IS, Aspelund T, Thorgerisson G et al (2005) The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 28:612–616
10. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884
11. Davis RC, Hobbs FD, Kenkre JE et al (2002) Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. BMJ 325:1156
12. Boonman-de Winter LJ, Rutten FH, Cramer MJ et al (2009) Early recognition of heart failure in patients with diabetes type 2 in primary care. A prospective diagnostic efficiency study. (UHFODM2). BMC Public Health 9:479
13. Rose GA, Blackburn H (1968) Cardiovascular survey methods. Monogr Ser World Health Organ 56:1–188
14. Schiller NB, Shah PM, Crawford M et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358–367
15. Folland ED, Parisi AF, Moynihan PF, Jones DR, Feldman CL, de Tow (1979) Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiography. A comparison of cineangiographic and radionuclide techniques. Circulation 60:760–766
16. Quinones MA, Waggoner AD, Reduto LA et al (1981) A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation 64:744–753
17. Willenheimer RB, Israelssohn BA, Cline CM, Erhardt LR (1997) Simplified echocardiography in the diagnosis of heart failure. Scand Cardiovasc J 31:9–16
18. Freeman AP, Giles RW, Walsh WF, Fisher R, Murray IP, de Wilckem (1985) Regional left ventricular wall motion assessment: comparison of two-dimensional echocardiography and radionuclide angiography with contrast angiography in healed myocardial infarction. Am J Cardiol 56:8–12
19. Devereux RB, Reichek N (1977) Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55:613–618
20. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB (2002) Left atrial volume as a morphophysiological expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 90:1284–1289
21. Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463
22. Yock PG, Popp RL (1984) Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 70:657–662
23. Munagala VK, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM (2003) Association of newer diastolic function parameters with age in healthy subjects: a population-based study. J Am Soc Echocardiogr 16:1049–1056
24. Burns F, Weston SA, Redfield MM et al (2006) Systolic and diastolic heart failure in the community. JAMA 296:2209–2216
25. Paulus WJ, Tschop C, Sanderson JE et al (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Association of the European Society of Cardiology. Eur Heart J 28:2539–2550
26. Gottsdiener JS, Bednarz J, Devereux R et al (2004) American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 17:1086–1119
27. Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29:2388–2442
28. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M (1972) Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med 287:781–787
29. Fischer M, Baessler A, Hense HW et al (2003) Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic–based survey of a population sample. Eur Heart J 24:320–328
30. Diamant M, Lamb HJ, Smit JW, de Roos A, Heine RJ (2005) Diabetic cardiomyopathy in uncomplicated type 2 diabetes is associated with the metabolic syndrome and systemic inflammation. Diabetologia 48:1669–1670
31. Kardys I, Deckers JW, Stricker BH, Vletter WB, Hofman A, Witteman J (2010) Distribution of echocardiographic parameters and their associations with cardiovascular risk factors in the Rotterdam Study. Eur J Epidemiol 25:481–490
32. Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22:107–133
33. Moons KG, de Grobbee (2002) When should we remain blind and when should our eyes remain open in diagnostic studies? J Clin Epidemiol 55:633–636
34. Bossuyt PM, Reitsma JB, Bruns DE et al (2003) The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49:7–18
35. Ruten FH, Moons KG, Cramer MJ et al (2005) Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 331:1379
36. Hogg K, Swedberg K, McMurray J (2004) Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43:317–327
37. Henry RM, Paulus WJ, Kamp O et al (2008) Deteriorating glucose tolerance status is associated with left ventricular dysfunction—the Hoorn Study. Neth J Med 66:110–117
38. Paulus WJ, van Ballegoij JJ (2010) Treatment of heart failure with normal ejection fraction: an inconvenient truth? J Am Coll Cardiol 55:526–537
39. Satpathy C, Mishra TK, Satpathy R, Satpathy HK, Barone E (2006) Diagnosis and management of diastolic dysfunction and heart failure. Am Fam Physician 73:841–846
40. American Diabetes Association (2010) Standards of medical care in diabetes–2010. Diabetes Care 33(Suppl 1):S11–S61